Últimas noticias sobre Exact Sciences (NASDAQ:EXAS) Bolsa

EXACT SCIENCES CORP

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

San,Jose,,Ca,,Usa,-,Nov,29,,2023:,Twilio,Ads

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAPL

ADIL

AMZN

ARDX

CNEY

EXAS

GNLN

HCTI

KIDZ

NPKI

PAPL

PLRZ

SOPA

SPHL

TEAM

TREE

TWLO

Las acciones de Twilio subieron más de un 9 % tras publicar sólidos resultados financieros trimestrales. ¿Quién más sorprendió?

Las acciones de Twilio (TWLO) suben más de un 9%; Aquí están 20 acciones que se mueven en el premercado

Equities

ETFs

$BTC

ARKF

ARKG

ARKK

ARKW

COIN

PLTR

PSNL

VRTX

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

Health Care

General

Exact Sciences Announced That Its Oncodetect Molecular Residual Disease Test Has Received Medicare Coverage Through The Centers For Medicare & Medicaid Services' Molecular Diagnostic Services Program For Serial Use In Patients With Stage II, III And Resectable Stage IV Colorectal Cancer In The Adjuvant And Recurrence Monitoring Settings Over A Five-year Period

Across the recent three months, 9 analysts have shared their insights on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $63.89, a high estimate of $75.00, and a low estimate of $54.00. Surpassing the previous average price target of $62.75, the current average has increased by 1.82%.
<img src="https://www.benzinga.com/files/images/story/2025/1752001292_0_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Exact Sciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Exact Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>All You Need to Know About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.86%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's net margin excels beyond industry benchmarks, reaching -14.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exact Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of -4.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exact Sciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.74%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 9 Analyst Projections For Exact Sciences

Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $66 to $68.

Price Target

Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $68

Personalized medicine, which involves tailoring treatment to a patient&#8217;s unique disease profile, is widely regarded as the holy grail of medicine. However, the current implementation of this approach faces significant hurdles.
Bank of America Securities (BofA) highlights that the precision medicine approach is currently <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">cost, labor, and time-intensive</a>.
Analysts Alec Stranahan and Michael Ryskin specifically point out that the substantial amount of manual work involved in processing complex biological data and making treatment decisions leads to considerable delays.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Beyond the practical challenges, precision medicine also grapples with data validation issues. Given the infinitely complex nature of biology and the huge number of interactions between biological systems, researchers often run into issues with validating the impact of genes/pathways associated with disease progression/response to treatment.
Despite these inherent challenges, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is widely recognized as a pivotal enabler for advancing precision medicine.
Consequently, a number of companies are actively leveraging these technologies to innovate within the precision medicine landscape, striving to make tailored treatments more accessible, efficient, and effective.
These companies include Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), Quest Diagnostics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), and LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), each employing AI in unique ways to enhance diagnostics, therapy selection, and overall patient care across the care continuum.
<h2 class="wp-block-heading">Tempus AI</h2>
BofA analyst says Tempus AI perfectly fits the theme of <a target="_blank" href="https://www.benzinga.com/news/movers-shakers/25/06/45726456/tempus-ai-stock-is-surging-today-what-investors-are-watching" rel="noreferrer noopener">AI in precision medicine</a>.
Like most MDx companies, Tempus AI has built its business off an industry-leading database of clinico-genomic data. Tempus leverages this data by training AI/ML algorithms to parse through the data and detect patterns and anomalies.&nbsp;&nbsp;
BofA reiterates a Neutral rating for Tempus AI, given its already premium valuation. The analyst remains constructive on the business and key markets. However, due to peer group expansion, BofA raised its price <a target="_blank" href="https://www.benzinga.com/quote/TEM/analyst-ratings" rel="noreferrer noopener">forecast from $68 to $70</a>.
<h2 class="wp-block-heading">Guardant Health</h2>
Guardant Health was an early mover in the liquid biopsy cancer testing/therapy selection market with their <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Guardant 360 (G360) test</a>.
Guardant Health has a clear goal to build upon its G360 test (therapy selection) and expand across the care continuum, thus allowing it to participate in a patient&#8217;s receiving precision medicine at all stages post-cancer diagnosis.
Guardant Health has its business built on the algorithms that it runs.
BofA <a target="_blank" href="https://www.benzinga.com/quote/GH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on Guardant Health, given its leading position, strong growth profile, and upcoming catalyst path for new products.
<h2 class="wp-block-heading">Exact Sciences</h2>
BofA analysts say Exact Sciences Corp. has expanded to offer services <a href="https://www.benzinga.com/general/health-care/25/05/45165534/cancer-diagnostic-firm-exact-sciences-ceo-says-strong-q1-paves-way-for-transformative-2025-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">across the care continuum</a>.
While Exact Sciences started screening for colorectal cancer specifically, their focus has been steered towards all indications and across the treatment paradigm.
Exact Sciences&#8217; legacy Cologuard test / early detection doesn&#8217;t necessarily &#8220;fit&#8221; the precision medicine theme; however, everything Exact has done since is &#8220;precision medicine / AI-aligned,&#8221; BofA added in its investor note on Wednesday.
Given its strong financial profile and near-term catalyst path, the analyst maintains a <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Buy rating on Exact Sciences</a>.
<h2 class="wp-block-heading">NeoGenomics</h2>
NeoGenomics has been known as a traditional reference lab offering many hotspot tests. However, by adding the PanTracer testing family and data services offering, NeoGenomics leverages the numerous hotspot data points and can build those into a more robust AI algorithm to inform the more modern therapy selection tests.
The dataset/algorithm and 500+ tests create a flywheel where the tests that are sold generate information. The information informs the algorithm, eventually leading to more accurate algorithms, which help market the tests… bring you back to more tests.
BofA <a target="_blank" href="https://www.benzinga.com/quote/NEO/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a> on NeoGenomics given near-term headwinds and more limited upside versus its prior trajectory.
<h2 class="wp-block-heading">Quest Diagnostics</h2>
Quest Diagnostics is showing trends toward AI in precision medicine with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Haystack and PathAI Quest</a>.
While not traditionally considered a &#8220;leader&#8221; in AI/precision medicine, Quest Diagnostics has shown progress toward becoming a company to watch.
At DGX&#8217;s 2025 Investor Day, management discussed innovations in lab diagnostics, including the adoption of AI and automation. Given Quest Diagnostics&#8217; strong, steady performance and lower exposure to macro/policy overhangs, the analyst <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a>.
<h2 class="wp-block-heading">LabCorp</h2>
LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) aims to be a notable player in AI precision medicine. Although LabCorp is known as a traditional reference lab, with trends toward AI and precision medicine, LH has shown signs of <a target="_blank" href="https://www.benzinga.com/25/02/43539754/labcorp-reports-q4-earnings-beat-and-expects-strong-2025-growth-analyst-reiterates-outperform-on-stable-2025-outlook" rel="noreferrer noopener">jumping on the bandwagon</a>.
While LabCorp already offers NGS tests, there appears to be a clear trend and focus towards advancing its AI/precision medicine portfolio.
BofA <a target="_blank" href="https://www.benzinga.com/quote/LH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on LabCorp, given strong and steady performance and lower exposure to macro/policy overhangs.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Analyst Color

Biotech

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $75 to $65.

Barclays Maintains Overweight on Exact Sciences, Lowers Price Target to $65

<ul>
<li>Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect, for recurrence monitoring in stage II–IV colorectal cancer.</li>
<li>Whole-genome Oncodetect test powered by MAESTRO to launch in 2026 with ultra-low limit of detection.</li>
</ul>

Exact Sciences Announced New Data To Be Presented From The Beta-CORRECT Clinical Validation Study At The 2025 American Society Of Clinical Oncology Annual Meeting

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares rose 27.39% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45149547" target="_blank" rel="noreferrer noopener">its FY25 sales guidance</a>. Several analysts <a href="https://www.benzinga.com/quote/duol/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares increased 24.15%.</li>
<li>Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock escalated 21.24% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45061907" target="_blank" rel="noreferrer noopener">its FY25 adjusted EPS guidance</a>. Many analysts <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) stock upped 19.10% after it reported better-than-expected first-quarter financial results<a href="https://www.benzinga.com//node/45135625" target="_blank" rel="noreferrer noopener"> and raised its FY25 guidance</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock upped 18.90%. Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 <a href="https://www.benzinga.com//node/45046531" target="_blank" rel="noreferrer noopener">trial, HARMONi-2 or AK112-303</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock upped 18.31% last week after the company announced it launched its commercial self-driving <a href="https://www.benzinga.com//node/45128218" target="_blank" rel="noreferrer noopener">trucking service in Texas</a>.</li>
<li>Arista Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) shares were up 16.83% after Rosenblatt upgraded the stock from Sell to Neutral and raised its <a href="https://www.benzinga.com/quote/anet/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $55 to $85</a>.</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) stock grew 14.83% after the company reported better-than-expected financial results and raised its FY25 GAAP EPS and <a href="https://www.benzinga.com//node/45108290" target="_blank" rel="noreferrer noopener">sales guidance above estimates</a>. Many analysts <a href="https://www.benzinga.com/quote/tt/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares escalated 13.90% f<a href="https://www.benzinga.com//node/45149628" target="_blank" rel="noreferrer noopener">ollowing strong quarterly sales</a>. Many analysts <a href="https://www.benzinga.com/quote/dxcm/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) shares increased 13.81%  after the company reported better-than-expected <a href="https://www.benzinga.com//node/45099967" target="_blank" rel="noreferrer noopener">first-quarter EPS results</a>. Many analysts <a href="https://www.benzinga.com/quote/xpo/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
</ol>
Photo by DANIEL CONSTANTE via Shutterstock

Large Cap

ANET

CARR

CRWV

DUOL

DXCM

SMMT

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and raises the price target from $55 to $75.

Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75

RBC Capital analyst Gerard Cassidy maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Perform and raises the price target from $52 to $54.

RBC Capital Maintains Sector Perform on Exact Sciences, Raises Price Target to $54

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday.
Shares of Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TRUP/earnings">raised its FY25 sales guidance</a>.
Trupanion reported quarterly loss of 3 cents per share which beat the analyst consensus estimate of loss of 5 cents per share. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million.
Trupanion shares jumped 18.2% to $43.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares surged 30% to $9.60 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
<li>NPK International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NASDAQ">NPKI</a>) gained 26.6% to $7.65 after the company reported better-than-expected first-quarter financial results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 23.1% to $4.42.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) gained 23.1% to $7.20.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 20.8% to $10.37.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 17.4% to $26.96.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 17.4% to $127.43 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) gained 15% to $460.50 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) gained 13.7% to $79.87 following strong quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) jumped 12.4% to $7.74.</li>
<li>Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) gained 11.3% to $44.33 following first-quarter results.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 11.1% to $52.40 after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 10.6% to $9.39.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) gained 6.4% to $142.68 following first-quarter results.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 6.3% to $49.58.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a></li>
</ul>

Intraday Update

ACHR

ADPT

ASTS

CART

HOOD

IRTC

PONY

TRUP

WOLF

Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday

Exact Sciences Corp.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NYSE">EXAS</a>) on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of 38 cents.</a>
The company reported quarterly sales of $706.78 million, up 11% year over year on a reported and core revenue basis, beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45149849/exact-sciences-announces-first-quarter-2025-results" rel="noreferrer noopener">estimate of $688.64 million</a>.
Screening revenue was $540 million, an increase of 14%, and Precision Oncology's revenue was $166.8 million, an increase of 2%&nbsp;or 4% on a core revenue basis.
"Our strong first quarter results pave the way for 2025 to mark our most transformative year yet," said Kevin Conroy, chairman and CEO. &#8220;With growing momentum in our commercial organization and improved profitability, we raised our full-year outlook and continue to build a foundation for sustained long-term growth."
Guidance: Exact Sciences raised its fiscal 2025 sales guidance from $3.02 billion-3.08 billion to $3.07 billion-3.12 billion versus the consensus of $3.06 billion.
The guidance includes a screening sales forecast of $2.39 billion—$2.43 billion, compared to previous guidance of $2.35 billion—$2.39 billion.
Precision Oncology sales are expected to be $680 million—$695 million, compared to prior guidance of $675 million—$695 million.
The company expects 2025 Adjusted EBITDA of $425 million—$455 million, up from previous guidance of $410 million—$440 million.
&#8220;Simply put, this was a solid first quarter out of the gate and we believe Exact is well positioned to continue to show modest upside throughout the year. This upside, coupled with pipeline catalysts like blood-based CRC screening test data later this summer, keep us positive on the long-term prospects,&#8221; William Blair writes.
Analyst Andrew F. Brackmann added, &#8220;In sum, this was a positive update and helped build support for a bullish thesis that can drive the stock higher over the course of the year. Shares trade at a very compelling forward revenue multiple of 3.5 times, leaving ample room for multiple expansion.&#8221;
William Blair reiterated <a href="https://www.benzinga.com/quote/EXAS/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: At the last check on Friday, EXAS stock was up 11.3% at $52.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45158118/analyst-cautions-on-snap-as-meta-and-google-benefit-from-ad-spending-shifts" target="_blank" rel="noreferrer noopener">Analyst Cautions On Snap As Meta And Google Benefit From Ad Spending Shifts</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $60 to $66.

Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $66

Baird analyst Catherine Schulte maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $69 to $72.

Baird Maintains Outperform on Exact Sciences, Raises Price Target to $72

WIIM

Exact Sciences shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY25 sales guidance.

Shares of Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) rose sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/quote/TWLO/earnings">better-than-expected first-quarter financial results.</a>
Twilio reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $0.94 per share. The company reported quarterly sales of $1.17 billion which beat the analyst consensus estimate of $1.14 billion.
Twilio shares jumped 9.3% to $107.00 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) rose 78.4% to $0.2529 in pre-market trading after gaining around 10% on Thursday.</li>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) surged 57.1% to $0.3980 in pre-market trading after dipping over 18% on Thursday.</li>
<li>Classover Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) gained 50.4% to $8.06 in pre-market trading. Classover Holdings shares jumped 366% on Thursday after the company announced it entered an equity purchase facility agreement with Solana Strategies Holdings.</li>
<li>Springview Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) surged 38% to $0.6781 in pre-market trading after gaining 11% on Thursday.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) gained 25.5% to $0.0118 in pre-market trading after dipping 17% on Thursday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 19.6% to $0.9325 in pre-market trading after gaining 13% on Thursday. The United States Patent and Trademark Office (USPTO) issued patent number 12,274,692 to Adial Pharmaceuticals' AD04 on Thursday.</li>
<li>NPK International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NYSE">NPKI</a>) gained 18.2% to $7.14 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Society Pass Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) rose 16.1% to $1.37 in pre-market trading after jumping over 42% on Thursday.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 10.7% to $52.23 in pre-market trading after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) shares dipped 21.9% to $45.66 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 19.8% to $0.2166 in pre-market trading after jumping 72% on Thursday.</li>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) fell 18.9% to $1.07 in pre-market trading. Advantage Solutions will release financial results for the first quarter on May 12.</li>
<li>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares fell 18.3% to $0.5927 in pre-market trading. WW International on Tuesday announced a pharmacy integration with Eli Lilly&#8217;s LillyDirect pharmacy provider, Gifthealth.</li>
<li>Pineapple Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NASDAQ">PAPL</a>) shares tumbled 18.1% to $0.16 in pre-market trading after falling 9% on Thursday.</li>
<li>Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) dipped 16.4% to $4.57 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) declined 16% to $192.35 in pre-market trading after the company issued fourth-quarter sales guidance below estimates.</li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) fell 12.9% to $47.14 in pre-market trading after the company reported worse-than-expected first-quarter sales results, issued second-quarter sales guidance below estimates, and cut its FY25 sales guidance.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 2.9% to $207.24 in today's pre-market trading. Apple reported fiscal second-quarter revenue of $95.36 billion, beating analyst estimates of $94.53 billion. The Cupertino-based company reported second-quarter earnings of $1.65 per share, beating analyst estimates of $1.63 per share. The company&#8217;s CEO Tim Cook said that the tech giant expects a $900 million cost impact in the June quarter due to tariffs.</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fell 2.3% to $185.93 in pre-market trading. Amazon reported stronger-than-expected first-quarter financial results after market close Thursday. The company said it expects second-quarter net sales of $159 billion to $164 billion, up 7% to 11%. Analysts expect the company to have net sales of $160.91 billion in the quarter.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 65 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $706.78 million which beat the analyst consensus estimate of $688.64 million by 2.64 percent. This is a 10.86 percent increase over sales of $637.52 million the same period last year.

Earnings Beats

CORRECTION: Exact Sciences Q1 Adj. EPS $(0.21) Beats $(0.38) Estimate, Sales $706.78M Beat $688.64M Estimate

<h3>Gainers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 42.3% to $1.11 during Thursday's after-market session. The company's market cap stands at $7.2 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares moved upwards by 18.46% to $12.8. The company's market cap stands at $2.4 billion. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock increased by 11.47% to $6.9. The company's market cap stands at $109.0 million. The company's, Q1 earnings came out today. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares rose 8.93% to $0.84. The market value of their outstanding shares is at $3.7 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares moved upwards by 8.77% to $51.3. The market value of their outstanding shares is at $9.6 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) shares increased by 8.76% to $4.22. The company's market cap stands at $69.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares decreased by 14.4% to $4.68 during Thursday's after-market session. The company's market cap stands at $1.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares declined by 13.59% to $37.09. The company's market cap stands at $4.3 billion. </li>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock fell 12.1% to $1.09. The company's market cap stands at $32.8 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.12% to $0.16. The market value of their outstanding shares is at $4.6 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 11.12% to $0.24. The company's market cap stands at $10.8 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 9.53% to $0.38. The company's market cap stands at $10.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWL

ANTX

CYTK

ONMD

OWLT

SILO

SSII

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's After-Market Session

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) raises FY2025 sales outlook from $3.02 billion-3.08 billion to $3.07 billion-3.12 billion.

Exact Sciences Raises FY2025 Sales Guidance from $3.02B-3.08B to $3.07B-3.12B

AAMI

ABNB

ACCO

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

APLE

APTV

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

Press Releases

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

Exact Sciences Announces First-Quarter 2025 Results

Exact Sciences to Participate in May Investor Conference

Exact Sciences Earns 2025 Great Place To Work® Certification™

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

Exact Sciences to Participate in June Investor Conference

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

Comments

Exact Sciences

Noticias

Últimas noticias sobre Exact Sciences (NASDAQ:EXAS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL